Galectin Therapeutics (FRA:PHPN) Debt-to-Equity : -1.19 (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Galectin Therapeutics Debt-to-Equity?

Galectin Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.04 Mil. Galectin Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €65.79 Mil. Galectin Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €-55.24 Mil. Galectin Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was -1.19.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Galectin Therapeutics's Debt-to-Equity or its related term are showing as below:

FRA:PHPN' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.24 Med: 0 Max: 11.11
Current: -1.19

During the past 13 years, the highest Debt-to-Equity Ratio of Galectin Therapeutics was 11.11. The lowest was -1.24. And the median was 0.00.

FRA:PHPN's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.145 vs FRA:PHPN: -1.19

Galectin Therapeutics Debt-to-Equity Historical Data

The historical data trend for Galectin Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galectin Therapeutics Debt-to-Equity Chart

Galectin Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

11.11

-1.24

-1.19

Galectin Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															-1.24	-1.17	-1.18	-1.20	-1.19

Competitive Comparison of Galectin Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Galectin Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galectin Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galectin Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Galectin Therapeutics's Debt-to-Equity falls into.

Galectin Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Galectin Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.042	+	65.786)	/	-55.241
	=	-1.19

Galectin Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.042	+	65.786)	/	-55.241
	=	-1.19

Galectin Therapeutics (FRA:PHPN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Galectin Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Galectin Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Galectin Therapeutics (FRA:PHPN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galectin Therapeutics Inc (FRA:PHPN) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

GALT:USA

Address

4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA, USA, 30071

Website

https://www.galectintherapeutics.com

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Galectin Therapeutics (FRA:PHPN) Headlines

No Headlines